Biotech/Pharma
ParcelBio
Elevated mRNA for transformative medicines Engineered to reach therapeutic thresholds that existing mRNA can't.
CORE INFO
$13M
Total FundingSeed
RoundWhy existing mRNA falls short. mRNA has already changed medicine. But the next generation of mRNA medicines – therapies that reprogram the immune system, kill tumors, and replace missing proteins – require a step-change in potency and durability. Conventional mRNA can't get there. APEXm™ can
HIRING SIGNAL
0
Open roles on their careers page
Snapshot via live ATS poll
—
Net new roles in the last 90 days
Available once weekly history accrues
90-Day VelocityV2 · BACKFILL
Trend builds weekly as historical rows accrue
SourcesGreenhouseLeverAshbyWorkableSmartRecruitersRipplingRecruiteeFallback · Wellfound, YC Work-at-a-Startup, careers-page scrape
KEY COMPANY ANNOUNCEMENTS
Filter
11 announcements · ranked by importanceMay 7, 2026FUNDINGParcelBio Launches with $13 Million in Financing to Advance Next-Generation mRNA Medicinesbusinesswire.com
May 7, 2026FUNDINGParcelBio Launches with $13 Million in Financing to Advance Next-Generation mRNA Medicines - BioSpacebiospace.com
Jan 1, 2024PRODUCTLaunch YC: ParcelBio: Programmable delivery of mRNA medicines | Y Combinator | Y Combinator | 11 commentslinkedin.com
Jan 1, 2024MILESTONEParcelBio: Elevated mRNA for transformative medicines. | Y Combinatorycombinator.com
Dec 7, 2021FOUNDER PROFILEScholar Spotlight: Christopher Carlsonnorthern-california.arcsfoundation.org